| Symbol | MDWD |
|---|---|
| Name | MEDIWOUND LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Medicinal Chemicals and Botanical Products |
| Address | 42 HAYARKON STREET, YAVNE, 8122745, Israel |
| Telephone | +972 779714100 |
| Fax | — |
| — | |
| Website | https://www.mediwound.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001593984 |
| Description | MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States. Additional info from NASDAQ: |
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
Read moreMediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Read moreMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
Read moreNew Form 3 - MediWound Ltd. <b>Filed:</b> 2026-03-25 <b>AccNo:</b> 0001178913-26-001689 <b>Size:</b> 18 KB
Read moreNew Form S-8 - MediWound Ltd. <b>Filed:</b> 2026-03-05 <b>AccNo:</b> 0001178913-26-000755 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04040660 | Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Inj… | — | Thermal Burn | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06568627 | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of Escha… | Phase3 | Venous Leg Ulcer (VLU) | Recruiting | 2025-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT06690177 | Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product… | Phase2 | Venus Leg Ulcers | Not_Yet_Recruiting | 2025-04-30 | 2028-09-30 | ClinicalTrials.gov |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatmen… | Phase1 | Superficial Basal Cell Carcinoma | Recruiting | 2021-06-30 | 2022-06-01 | ClinicalTrials.gov |
| NCT04817228 | A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of… | Phase2 | Venous Leg Ulcer | Completed | 2021-04-21 | 2022-05-20 | ClinicalTrials.gov |
| NCT03588130 | A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation)… | Phase2 | Venous Leg Ulcer | Completed | 2019-12-02 | 2022-03-23 | ClinicalTrials.gov |
| NCT02148705 | A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Therma… | Phase3 | Thermal Burns | Completed | 2015-05-27 | 2020-08-20 | ClinicalTrials.gov |
| NCT02278718 | A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Therma… | Phase3 | Thermal Burns | Completed | 2015-05-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT02020746 | Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds | Phase2 | Hard to Heal Wounds | Completed | 2014-07-24 | 2018-06-04 | ClinicalTrials.gov |
| NCT01800981 | Functionality Assessments in Patients (Adults and Children) Following Treatment… | — | Burns, Upper Extremity | Unknown | 2013-03-01 | — | ClinicalTrials.gov |
| NCT01679678 | A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insuffi… | Phase2 | Surgical Wound Dehiscence | Terminated | 2012-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01350700 | Long Term Follow up of Scars Formation and Quality of Life Assessment Study | — | Scars Formation | Completed | 2011-06-01 | 2011-11-22 | ClinicalTrials.gov |
| NCT00898521 | Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Bur… | Phase2 | Burn | Completed | 2009-12-20 | 2015-12-02 | ClinicalTrials.gov |
| NCT00324311 | Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care | Phase3 | Burn | Completed | 2005-12-01 | 2010-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Non-surgical standard of care (NSSOC) | Other | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| Gel Vehicle | Other | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| EscharEx (5% EX-02 formulation) | Other | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| Polyheal | Other | Phase PHASE2 | Surgical Wound Dehiscence | TERMINATED | NCT01679678 |
| PolyHeal 2 | Other | Phase PHASE2 | Surgical Wound Dehiscence | TERMINATED | NCT01679678 |
| Scars assessment & QOL | Other | Preclinical | Scars Formation | COMPLETED | NCT01350700 |
| Gel Vehicle | Other | Phase PHASE2 | Hard to Heal Wounds | COMPLETED | NCT02020746 |
| EscharEx | Other | Phase PHASE2 | Hard to Heal Wounds | COMPLETED | NCT02020746 |
| EscharEx 5% (EX-02 formulation) | Other | Phase PHASE1 | Superficial Basal Cell Carcinoma | RECRUITING | NCT05157763 |
| EscharEx (EX-02 formulation) | Other | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT04817228 |
| Gel Vehicle | Other | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02148705 |
| Standard of Care (SOC) | Other | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02148705 |
| NexoBrid | Other | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02148705 |
| NexoBrid | Other | Preclinical | Thermal Burn | APPROVED_FOR_MARKETING | NCT04040660 |
| Standard of Care | Other | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02278718 |
| NexoBrid | Other | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02278718 |
| Placebo (Gel vehicle) | Other | Phase PHASE2 | Venus Leg Ulcers | NOT_YET_RECRUITING | NCT06690177 |
| EscharEx (EX-03) | Other | Phase PHASE2 | Venus Leg Ulcers | NOT_YET_RECRUITING | NCT06690177 |
| Placebo (Gel vehicle) | Other | Phase PHASE3 | Venous Leg Ulcer (VLU) | RECRUITING | NCT06568627 |
| EscharEx (EX-03) | Other | Phase PHASE3 | Venous Leg Ulcer (VLU) | RECRUITING | NCT06568627 |
| Placebo (Gel vehicle) | DRUG | Phase PHASE2 | Venus Leg Ulcers | NOT_YET_RECRUITING | NCT06690177 |
| EscharEx (EX-03) | DRUG | Phase PHASE2 | Venus Leg Ulcers | NOT_YET_RECRUITING | NCT06690177 |
| EscharEx 5% (EX-02 formulation) | DRUG | Phase PHASE1 | Superficial Basal Cell Carcinoma | UNKNOWN | NCT05157763 |
| EscharEx (EX-02 formulation) | DRUG | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT04817228 |
| Non-surgical standard of care (NSSOC) | DRUG | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| EscharEx (5% EX-02 formulation) | DRUG | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| Standard of Care | PROCEDURE | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02278718 |
| Scars assessment & QOL | OTHER | Preclinical | Scars Formation | COMPLETED | NCT01350700 |
| Standard of Care (SOC) | PROCEDURE | Phase PHASE3 | Thermal Burns | COMPLETED | NCT02148705 |
| NexoBrid | DRUG | Preclinical | Thermal Burn | APPROVED_FOR_MARKETING | NCT04040660 |
| Gel Vehicle | DRUG | Phase PHASE2 | Venous Leg Ulcer | COMPLETED | NCT03588130 |
| EscharEx | DRUG | Phase PHASE2 | Hard to Heal Wounds | COMPLETED | NCT02020746 |
| Polyheal | DEVICE | Phase PHASE2 | Surgical Wound Dehiscence | TERMINATED | NCT01679678 |
| PolyHeal 2 | DEVICE | Phase PHASE2 | Surgical Wound Dehiscence | TERMINATED | NCT01679678 |
| DGD | DRUG | Phase PHASE2 | Burn | COMPLETED | NCT00898521 |